From a Sardinian sewer to global medicine: the accidental history of cephalosporin antibiotics
In short: Discovered in a Sardinian sewer in 1945, cephalosporins revolutionized medicine by offering a potent alternative to penicillin. These beta-lactam antibiotics disrupt bacterial cell walls, saving countless lives. Yet, as resistance grows and classification systems blur, understanding their true clinical utility requires looking beyond the labels of their generations.
The story of cephalosporins began in 1945 when Italian pharmacologist Giuseppe Brotzu discovered a mold, Acremonium, in the sea near Cagliari, Sardinia. While early isolation efforts in 1948 identified substances effective against Salmonella typhi, it was the later work of Guy Newton and Edward Abraham at Oxford that isolated cephalosporin C. This compound provided the 7-aminocephalosporanic acid nucleus, which, once modified, allowed Eli Lilly and Company to launch the first clinical agent, cefalotin, in 1964.
Mechanistically, cephalosporins act as bactericidal agents by mimicking the D-Ala-D-Ala site of muropeptides. By binding to penicillin-binding proteins, they irreversibly inhibit the cross-linking of the peptidoglycan layer, which is essential for bacterial cell wall integrity. While they are generally less susceptible to beta-lactamases than penicillins, resistance is an escalating concern. Bacteria such as Escherichia coli and Klebsiella pneumoniae have developed various defense strategies, including the acquisition of beta-lactam-insensitive proteins and altered membrane permeability.
The classification of these drugs into generations is a common but imprecise practice. While first-generation agents target Gram-positive bacteria, successive generations have expanded their reach toward Gram-negative organisms. However, this system is not universally standardized; for instance, Japan does not recognize a fourth generation, and specific drugs like cefaclor are categorized differently across borders. Furthermore, the long-held belief that 10% of penicillin-allergic patients would show cross-reactivity with cephalosporins has been challenged by recent data, which suggests the actual risk for later-generation drugs is significantly lower.
Clinical application also demands caution regarding side effects. Certain cephalosporins, such as cefotetan and ceftriaxone, contain side chains that can interfere with vitamin K metabolism or inhibit aldehyde dehydrogenase. This can lead to hypoprothrombinemia or severe reactions when combined with alcohol. As antimicrobial resistance continues to threaten the efficacy of these drugs, particularly in severe infections like shigellosis, the focus is shifting toward susceptibility-guided therapy and rigorous stewardship to preserve their role in modern medicine.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Cephalosporin
- Also: New microbes and new infections — <i>Shigella</i> infections in the era of antimicrobial resistance: Insights into cephalosporin use. · CC BY
To cite this card, link to https://intellectplus.co.uk/app/health-cephalosporin.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
